Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study

Januario E Castro, MD, Carlos I. Amaya-Chanaga, MD, Juliana Velez Lujan, BS,PhD, Michael Choi, MD, Colin McCarthy, BS, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 1730.

https://doi.org/10.1182/blood.V130.Suppl_1.1730.1730

Published: 2017

Journal Articles

Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003

Rob S Sellar, MBChB, FRCPath, Clare Rowntree, PhD, Ajay J. Vora, Caroline L Furness, MD, Nicholas Goulden, MD PhD, Chris Mitchell, FRCPCH, Anthony V. Moorman, PhD, Rachael Hough, MDBMBS,FRCP,FRCPath

Blood (2015) 126 (23): 2493.

https://doi.org/10.1182/blood.V126.23.2493.2493

Published: 2015

Journal Articles

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Cara A. Rosenbaum, MD, Brandelyn Pitcher, MS, Nancy L Bartlett, MD, Sonali M. Smith, MD, Jane Jijun Liu, MD, Eric D. Hsi, MD, Sin-Ho Jung, PhD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 2741.

https://doi.org/10.1182/blood.V126.23.2741.2741

Published: 2015

Journal Articles

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Howard Liebman, MD, James B Bussel, MD, Mansoor N Saleh, MD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 1080.

https://doi.org/10.1182/blood.V122.21.1080.1080

Published: 2013

Journal Articles

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

Edmund A Rossi, Ph.D, Rosana Michel, M.S., Chien-Hsing Chang, Ph.D, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 2282.

https://doi.org/10.1182/blood.V122.21.2282.2282

Published: 2013

Journal Articles

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2451.

https://doi.org/10.1182/blood.V120.21.2451.2451

Published: 2012

Journal Articles

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Matt Kalaycio, MD, O George Negrea, MD, Rebecca Elstrom, MD, Charles Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 192.

https://doi.org/10.1182/blood.V120.21.192.192

Published: 2012

Journal Articles

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Howard A. Liebman, MA, MD, Mansoor N Saleh, MD, James B. Bussel, MD, O George Negrea, MD, Heather Horne, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 622.

https://doi.org/10.1182/blood.V120.21.622.622

Published: 2012

Journal Articles

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Michael B Tomblyn, MD, MS, Thomas E. Witzig, MD, Andrew L Himelstein, MD, Rebecca Elstrom, MD, Ebenezer A Kio, MD, Robert M Sharkey, PhD, Jonathan Rojo, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 3680.

https://doi.org/10.1182/blood.V120.21.3680.3680

Published: 2012

Journal Articles

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien-Hsing Chang

Blood (2012) 119 (16): 3767–3778.

https://doi.org/10.1182/blood-2011-09-381988

Published: 2012

Includes: Supplemental data

Journal Articles

Combination Therapy with FTY720 (Fingolimod) and Bispecific Anti-CD20/CD74 Antibodies in Mantle Cell Lymphoma,

Pankaj Gupta, Ph.D, Rosana Michel, M.S., David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2011) 118 (21): 3736.

https://doi.org/10.1182/blood.V118.21.3736.3736

Published: 2011

Journal Articles

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Beth Christian, MD, Lapo Alinari, MD., Ph.D., Jeffrey A. Jones, MD, MPH, Don M Benson, Jr., MD, PhD, Joseph M. Flynn, DO, MPH, Pierluigi Porcu, MD, Mark E Lustberg, MD, PhD, Mitchell Phelps, Ph.D., Ming Poi, PharmD, PhD, Diana Chung, BS, Carl Quinion, John C. Byrd, MD, William Wegener, MD, PhD, David M Goldenberg, Robert A. Baiocchi, M.D., Ph.D., Kristie A. Blum, MD

Blood (2011) 118 (21): 3707.

https://doi.org/10.1182/blood.V118.21.3707.3707

Published: 2011

Journal Articles

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Howard A Liebman, MD, Mansoor N Saleh, MD, James B Bussel, MD, Zale P Bernstein, MD, O George Negrea, MD, Anthony C Onyegbula, DO, Charles M Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2011) 118 (21): 3302.

https://doi.org/10.1182/blood.V118.21.3302.3302

Published: 2011

Journal Articles

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Edmund A Rossi, Ph.D, Thomas M. Cardillo, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Richard R. Furman, MD, Chien-Hsing Chang, Ph.D

Blood (2011) 118 (21): 599.

https://doi.org/10.1182/blood.V118.21.599.599

Published: 2011

Journal Articles

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Beth Christian, MD, Lapo Alinari, MD, Christian Tyler Earl, Emily Wilding, Carl Quinion, Mark Lustberg, MD, PhD, Don M Benson, Jr., MD, PhD, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD, Robert A. Baiocchi, MD, PhD, Kristie A. Blum, MD

Blood (2010) 116 (21): 2788.

https://doi.org/10.1182/blood.V116.21.2788.2788

Published: 2010

Journal Articles

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

David M Goldenberg, Sc.D., M.D., Serengulam Govindan, Ph.D., Tom M Cardillo, Ph.D., Robert M Sharkey, Ph.D.

Blood (2010) 116 (21): 3941.

https://doi.org/10.1182/blood.V116.21.3941.3941

Published: 2010

Journal Articles

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Chien-Hsing Chang

Blood (2010) 116 (17): 3258–3267.

https://doi.org/10.1182/blood-2010-03-276857

Published: 2010

Journal Articles

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Mansoor N Saleh, MD, Howard Liebman, MD, Zale P. Bernstein, MD, O. George Negrea, MD, James B. Bussel, MD, Anthony C. Onyegbula, DO, Charles M Farber, MD, PhD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Kenneth Pennington, MD, Heather Horne, Nick Teoh, PhD, Asraf Gomaa, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2009) 114 (22): 1322.

https://doi.org/10.1182/blood.V114.22.1322.1322

Published: 2009

Journal Articles

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

Diane L Nordstrom, Edmund A Rossi, PhD, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2009) 114 (22): 1695.

https://doi.org/10.1182/blood.V114.22.1695.1695

Published: 2009

Journal Articles

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Waleed Alduaij, MRes, Sandeep Potluri, BA, Andrei Ivanov, PhD, Jamie Honeychurch, PhD, Stephen A Beers, PhD, Claude Chan, PhD, Kazayuki Shimada, MD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Tim Illidge, MD, PhD

Blood (2009) 114 (22): 725.

https://doi.org/10.1182/blood.V114.22.725.725

Published: 2009

NARROW

Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study

Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Combination Therapy with FTY720 (Fingolimod) and Bispecific Anti-CD20/CD74 Antibodies in Mantle Cell Lymphoma,

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only